tbuckley/cabot-search huggingface dataset:
Outpatient management of cancer-associated pulmonary embolism (PE): analysis of lung carcinoma (LC) cohort from the Epiphany study
Authors: C. Beato, L. Faez, A. Carmona-Bayonas, M.D. Mediano, C. Font, D. Calvo-Temprano, P. Jimenez Fonseca, A. Dominguez, M.P. Solis Hernandez, M. Biosca, Idela Haba, M. Antonio, O. Madriano, A. Ramchandani, E. Castanon Alvarez, M.J. Martinez, J.A. Virizuela Echaburu, R. Otero
Journal: Annals of Oncology (2016)
Epidemiology and Clinical Features of Chronic Lymphoid Leukemia. Review of the Algerian Chronic Lymphoid Leukemia Study Group
Authors: N Dali, H Ait Ali, A Tibiche, F Belhadri, F Harieche, R Ahmed Nacer, RM Hamladji, S Taoussi, S Oukid, MT Abad, C Kerrar, N Boudjerra, M Belhani, S Bougherira, F Grifi, D Saidi, H Touhami, S Mahdad, MA Bekadja, Z Bouhedda, S Hamdi, N Ould Kablia, Fz Ardjoun, F Ouaddah, Z Zouaoui, S Bougofa, M Saidi, M Benhalilou, N Sidi Mansour, R Khiat, N Mesli, N Mehalhal, Z Brahimi, N Lakhdari, B Bendjabellah, A Bachiri, M Benakli
Journal: Blood (2015)
PDTB-16. ASSESSING THE FUNCTION OF CHROMATIN MODIFYING ENZYMES IN MEDULLOBLASTOMA
Authors: Tolga Lokumcu, Filiz Senbabaoglu, Udo Oppermann, Tugba Bagci-Onder
Journal: Neuro-Oncology (2016)

Medulloblastoma is the most common pediatric brain tumor that arises during infancy and childhood and is a major cause of cancer related-morbidity and mortality in children. Recently, medulloblastomas are described as four distinct molecular subgroups (Wnt, sonic hedgehog, Group 3 and Group 4), which have distinct transcriptional, cytogenetic, and mutational spectra. Next-generation studies have revealed that adult medulloblastomas involve remarkably more somatic SNVs and indels than paediatric counterparts, suggesting that epigenetic deregulation might have a foremost role in the initiation and progression of pediatric medulloblastomas. For this purpose, the function of chromatin modifying enzymes (CMEs) in medulloblastoma was investigated by utilizing a chemical library, which was composed of 46 inhibitors against different CMEs. The screen revealed 7 potential inhibitors that induced cell death in a dose-dependent manner in DAOY and D283 MB cell lines significantly. Among those, inhibitors targeting histone deacetylases (HDACs) and different histone demethylases (HDMs) were present. As their roles have been ill-defined in medulloblastomas, we focused on HDMs and investigated the downstream molecular changes upon inhibitor treatment by qRT-PCR and western blotting. We observed that pro-apoptotic genes were upregulated in favour of enhanced apoptosis and cells underwent apoptosis as revealed by PARP cleavage. In conclusion, our results suggest that targeting specific HDMs by specific inhibitors can be a promising therapeutic approach for medulloblastoma patients.
Brain Glucose Metabolism in Parry-Romberg Syndrome
Authors: Klara Uhrhan, Monika Rabenstein, Carsten Kobe, Alexander Drzezga, Gereon R. Fink, Lothar Burghaus
Journal: Clinical Nuclear Medicine (2017)

Parry-Romberg syndrome is a rare disorder characterized by a progressive facial hemiatrophy of the skin, subcutaneous tissue, musculature, bone, and cartilage. It is often associated with neurological symptoms such as trigeminal neuropathy, paresthesia of the face, migraine, and seizures and can be paired with ocular problems and ipsilateral progressive body atrophy. Here, we present a young woman with progressive facial hemiatrophy, who was referred for FDG-PET/CT. Hypometabolism was observed in the left cingulate and postcentral gyrus, left cerebellum, and right basal ganglia. Hypometabolism may be observed before anatomical changes and therefore facilitate early diagnosis.
Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).
Authors: Nicola Cascavilla, Carlo Bodenizza, Angelo Michele Carella, Matteo Dell’Olio, Antonietta Pia Falcone, Michele Mario Greco, Antonio La Sala, Saverio Mantuano, Lorella Melillo, Emanuela Merla, Michele Nobile, Grazia Sanpaolo, Potito Scalzulli
Journal: Blood (2007)
Impact of hormonal receptor status on prognosis in HER2 positive breast cancer
Authors: L. Cantini, M. Pistelli, M. Paesani, Z. Ballatore, L. Bastianelli, M.G. De Lisa, M. Santoni, A. Pagliacci, N. Battelli, R. Bracci, E. Maccaroni, I. Valeri, T. Biscotti, A. Santinelli, R. Berardi
Journal: Annals of Oncology (2016)
IMST-17. PHENOTYPE MODULATION OF TUMOR ASSOCIATED MICROGLIA ENHANCES PEDIATRIC MEDULLOBLASTOMA CELL DEATH IN VITRO
Authors: Amy-Lee Bredlau, Ramin Eskandari, Daniel G. McDonald, Stephen Lowe, Kenneth N Vanek, Naren L Banik, Joseph M Jenrette, Samuel Cheshier, Arabinda Das
Journal: Neuro-Oncology (2016)

Little is known about the interactions of the CNS immune system microglia with pediatric medulloblastoma cells. Emerging evidence suggests that malignant tumors specifically modify tumor associated microglia (TAM) into an inactive M2-phenotype, in contrast to classically activated proinflammatory cytotoxic M1-type. These M2-type microglia exert medulloblastoma-supportive effects through reduced anti-tumor functions, increased expression of immunosuppressive mediators, and nonimmune tumor promotion through expression of trophic and invasion-facilitating substances. In the current study, we used low-dose radiation therapy in combination with monoclonal antibody (mAb) to stimulate TAM into a cytotoxic M1-like phenotype and enhance anti-tumor immune responses in co-culture models. Molecular signaling for activation of TAM into the M1-like phenotype occurs through 4-1BB (CD-137), a regulatory protein involved inimmune cell proliferation and survival. ELISA spot demonstrated treatment of 50 ng of 4-1BB (CD137) + 1Gy X-ray radiation reconverted M2phenotype (arginase +, CD163+, CD204+, IL-10+ and TGF-β+) to M1 phenotype (iNOS+++, IL-1+, IL-12+, IL-23+ iNOS+, NO+, TNF-alpha+, IFN-gamma+ and upregulated MHC –II and CD86). Conditional media from M2-phenotype microglia failed to demonstrate effects on medulloblastoma cells (MP1), where as conditional media from M1-phenotype microglia induced medulloblastoma cell death. Based on our results, the use of 4-1BB mAb plus radiation may prove to be beneficial for the treatment of medulloblastoma as an immune-modulatory therapy.
Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines.
Authors: Heiko Koenig, Erika M. Moseson, Christian Lorentz, Peter Paschka, Junia V. Melo, Ruediger Hehlmann, Andreas Hochhaus, Paul La Rosée
Journal: Blood (2004)
BMET-09. BRAIN METASTASES FROM OVARIAN CARCINOMA: PROGNOSTIC FACTORS AND TREATMENT OUTCOME
Authors: Zvi Cohen, Gil Kimhi
Journal: Neuro-Oncology (2016)

Between January 1995 and December 2014, 25 patients with ovarian brain metastases were treated at The Sheba Medical Center. The medical records were retrospectively reviewed to collect demographic, clinical and imaging data, treatment modalities and outcome. The mean age of patients at the time of brain metastases diagnosis was 61.2 years. The median interval between the diagnosis of the primary cancer and brain metastases was 39.25 months. Neurological deficit, headache, and seizure were the most common symptoms. The brain was the only site of metastasis in 20% of patients. Active ovarian cancer at the diagnosis of brain metastases was observed in half of the patients with systemic disease. Multiple brain metastases were seen in 25 % of the patients. We treated 12 patients with Surgery + Radiation therapy protocols in various orders: surgery followed by complementary WBRT, surgery followed by SRS, and surgery followed by WBRT and consequently followed by adjuvant SRS. 5 patients underwent surgery alone and 8 patients were treated with radiation alone (WBRT, SRS or both). Univariate analysis for predictors of survival demonstrated that age above 62.7 years old at the time of CNS involvement was a significant risk factor and leptomeningeal disease was found to be a poor prognostic factor in reference to supra-tentorial lesions. However in a multivariate analysis for predictors of survival our results showed that multiple brain lesions (>4) were a poor prognostic factor and a multivariate analysis of time to progression revealed that combined treatments of surgery and radiation resulted in longer median periods of PFS than each modality alone. We conclude that the only significant predictor of survival or PFS in our cohort were the number of brain metastases and the treatment modality accordingly.
Care by Kampo medicine for toxicities of colorectal cancer chemotherapy: Effect of goshajinkigan (TJ-107) and powdered processed aconite root (TJ-3023) on oxaliplatin-related neurotoxicity, and effect of hangeshashinto (TJ-14) on CPT-11-related diarrhea.
Authors: Y. Shindo, H. Andoh
Journal: Journal of Clinical Oncology (2011)

601 Background: FOLFOX is standard therapy of advanced-stage colorectal cancer. Sensory neurotoxicity (SN) with oxaliplatin is its dose-limiting toxicity. We decided to use goshajinkigan (TJ-107) for prevention of oxaliplatin-related SN. We think that the main action is the one with powdered processed aconite root (TJ-3023). FOLFIRI is standard therapy too. But watery diarrhea is severe side effect. We decided to use hangeshashinto (TJ-14) for prevention of CPT-11-related watery diarrhea. Methods: The subjects were 66 patients with advanced-stage colorectal cancer. All 66 patients take TJ-107 (7.5g/day) every day from first oxaliptatin infusion day. Patients profiles were: Male/Female: 29/37, median age 69 years old (42∼84), PS0/1/2/3: 57/9/0/0, clinical stage IIIC/IV: 14/52. Oxaliplatin (85mg/m 2 ) was given as FOLFOX4 (27case), mFOLFOX6 (34) and CapeOx (5). When SN was increased, TJ-3023 was added. TJ-3023 is ingredient of TJ-107. 12 patients had severe watery diarrhea due to FOLFIRI regimen. All 12 patients take TJ-14 (7.5g/day) from appearance of watery diarrhea. Patients profiles were: Male/Female: 8/4. Results: Total course number of FOLFOX/CapeOX was 595/21, and average number of FOLFOX/CapeOX was 8.46/4.2. Relative dose intensity of oxaliplatin were 37.6mg/m 2 /week. Medicine compliance of TJ-107 was 89%. 20 patients had grade 3 toxcity (neutropenia 18, thrombocytopenia 2). TTP is 8.14 months. Response Evaluation Criteria is CR/PR/SD/PD/NE:1/36/11/5/13. SN occurred in 43 patients (65.1%). TJ-3023 was added to 10 patients. SN was slightly decreased by TJ-3023. There was no neurotoxicity case with functional impairment in this study. By TJ-14, all 12 patients have a change for the better from grade 2 to grade 1 or 0 of diarrhea. There was no constipation cases. Conclusions: TJ-107 seem to prervent acute oxaliplatin-induced SN. TJ-3023 may be related to SN prervention mechanism. TJ-14 seem to prevent CPT-11-induced diarrhea. The continuance of chemotherapy for colorectal cancer can be expected by these Kampo medicine. No significant financial relationships to disclose.
An immunohistochemical PD-L1 diagnostic assay for treatment with durvalumab in urothelial cancer patients
Authors: M. Zajac, A.M. Boothman, A. Nielsen, G. Manriques, C. Barker, P. Wang, P. Patil, N. Schechter, M. Rebelatto, J. Walker
Journal: Annals of Oncology (2016)
IMST-33. ENHANCED T CELL ACTIVATION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
Authors: Changlin Yang, Anjelika Dechkovskaia, Jeffrey Drake, Fernanda Guimaraes, Paul Kubilis, Jianping Huang, Duane Mitchell
Journal: Neuro-Oncology (2016)

Human CMV antigens have been proposed as novel targets for immunotherapy in glioblastoma (GBM). We previously demonstrated in a pilot randomized and blinded clinical trial, that vaccination of patients with newly-diagnosed GBM with autologous dendritic cells (DC) pulsed with RNA encoding the CMV antigen pp65 led to the expansion of pp65-specific T cell responses and was associated with prolonged survival (Mitchell, Batich et al., Nature 2015). A short targeting peptide from the lysosomal associated membrane protein 1 (LAMP-1) was expressed as a fusion construct with pp65 to enhance antigen-processing and presentation in RNA-pulsed DCs. In this study, we compared the use of a full-length LAMP fusion RNA construct (flLAMP-pp65, provided by Immunomic Technologies, Inc.) with the used short peptide chimeric antigen (shLAMP-pp65). DCs from HLA-A2+ or B7+, CMV seropositive (n=7) were pulsed with flLAMP-pp65 or shLAMP-pp65 RNA and used to stimulate autologous lymphocytes in vitro. Activation of CMV-specific T cells was evaluated by tetramer expansion, cytokine secretion, flow cytometric phenotyping, and recognition of HLA-matched GBM tumor cells expressing CMV pp65. DCs pulsed with full-length LAMP-1-pp65 chimeric RNAs demonstrated enhanced CMV-specific T cells as assessed by tetramer expansion in 7 out of 7 evaluated subjects, comparable induction of effector memory and central memory T cells, and increased IFNgamma secretion in recognition of pp65-expressing GBM tumor cells. Our results demonstrated potential superiority in the expansion of CMV-specific T cells and recognition of CMV pp65-expressing GBM tumor cells in vitro with use of the full-length LAMP-1 pp65 chimeric RNA pulsed DCs. A multi-institutional, blinded, randomized, and placebo-controlled phase 2 clinical trial is underway at our center utilizing flLAMP-pp65 RNA pulsed DCs, shLAMP-pp65 RNA pulsed DCs, and unpulsed PBMCs as a control vaccine.
Can <sup>1</sup>H-Nuclear magnetic resonance (NMR) be used for early detection of hepatocellular cancer (HCC)?
Authors: R. V. Iyer, B. Tennant, M. Ruiz, T. Szyperski, D. Trump, K. Odunsi, R. Wollman
Journal: Journal of Clinical Oncology (2007)

15107 Background: HCC is a common and rapidly fatal cancer. Current screening tools are inadequate for identification of potentially curable cases. Our aim was to determine whether H-NMR can identify HCC compared to controls in the woodchuck (WC) model of hepatitis related HCC. Methods: Eastern WCs were bred and inoculated at birth with dilute sera from WCs that are chronic carriers of Woodchuck Hepatitis B Virus (WHV). This resulted in chronic hepatitis in ∼60% animals and all carriers developed HCC by 24–36 months. Serum from 10 chronic WHV carriers with HCC (group 1), 5 WHV carriers with no HCC (group 2) and 15 matched non-infected controls (group 3) was obtained. 45uL serum was diluted with 5uL of D2O containing 27mM formic acid + 0.9% saline. Spectra were collected on a 600 MHz INOVA spectrometer using a CapNMR flow probe with 10uL flow cell at 298K without knowledge of group assignments. The resulting 1D spectra were processed using Nuts from AcornNMR. Results: Principle component analysis and supervised PLS-DA was performed using Simca P+ from Umetrics. Despite general separation of groups, the Q2 value of this model was relatively low (0.20). We trained a Support Vector Machine (SVM) algorithm, a supervised machine-learning algorithm, to learn to identify the groups. Evaluation of the performance of the algorithm using 10-fold validation on the data set achieved a Kappa value of 0.43. This algorithm learnt to identify HCC [0.765 ROC, 0.8 sensitivity, and 0.727 positive predictive value (PPV)] and controls (0.75 ROC, 0.69 sensitivity and 0.73 PPV) but not the WHV carrier group, likely due to the small numbers. In a second analysis of 10 HCC and 15 controls, PLS-DA showed clear separation using three components (Q2= 0.5). The corresponding SVM model showed a kappa value of 0.52 and ROC values of 0.767 for both classes. Conclusions: Our preliminary results indicate that H-NMR spectra alone can be used to distinguish HCC from healthy controls using the machine-learning algorithm for classification. Further validation in a larger cohort of woodchucks is ongoing and confirmation of these preliminary findings would support investigation of this technique as a screening tool in patients at risk for developing HCC. No significant financial relationships to disclose.
Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study
Authors: Jason R Andrews, Elisa Nemes, Michele Tameris, Bernard S Landry, Hassan Mahomed, J Bruce McClain, Helen A Fletcher, Willem A Hanekom, Robin Wood, Helen McShane, Thomas J Scriba, Mark Hatherill
Journal: The Lancet Respiratory Medicine (2017)
ACTR-37. UPFRONT CHEMOTHERAPY PROLONGS PROGRESSION FREE SURVIVAL OF THE PATIENTS WITH LOW-GRADE OLIGODENDROGLIAL TUMORS
Authors: Kuniaki Saito, Keiichi Kobayashi
Journal: Neuro-Oncology (2016)

The best treatment strategy for low-grade oligodendroglial tumors is an ongoing debate. Because many low-grade oligodendroglioma patients may remain stable for a long time without any treatment, many physicians tend to defer treatment until progression. Chemotherapy added to radiotherapy was proven to be beneficial for high-risk low-grade glioma patients. Nonetheless, it is unclear whether upfront chemotherapy alone improve outcome of the patients with low-grade oligodendroglial tumors. We treated 24 patients with newly diagnosed low-grade oligodendroglial tumors with maximum safe resection followed by observation or by upfront chemotherapy with procarbazine, ACNU, and vincristine (PAV) or temozolomide (TMZ). Overall survival (OS), progression free survival (PFS), and toxicity were retrospectively reviewed. The response to treatment was defined according to the RANO criteria. Of the 24 patients, 12 were treated with upfront chemotherapy (7 PAV, 5 TMZ) and 12 were observed without any treatment until the time of progression. Codeletion of 1p19q, MGMT promoter methylation, IDH1 mutation were observed in 71%, 70% and 68% of the patients, respectively. Median follow up duration was 5.2 years (range 1.3–15.2 years). No patients died and median PFS (mPFS) was not reached. Upfront chemotherapy was associated with a significant increase in PFS (mPFS not reached versus 33.4 months for observed patients; p=0.006). The absence of astrocytic component (p=0.024) and younger age (<50; p=0.047) were also prognostic factor for PFS. MGMT promoter methylation tended to be associated with longer PFS (p=0.071). Multivariate analysis revealed that upfront chemotherapy, younger age, and the absence of astrocytic component were independent prognosticator for PFS. Albeit retrospective analysis, this study revealed strong association between upfront chemotherapy and PFS. Upfront chemotherapy without radiotherapy is a good therapeutic option for the patients with low-grade oligodendroglial tumor. Prospective, randomized control trials to verify this treatment regimen are needed.
Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients
Authors: C. Solinas, A. Boisson, D. Brown, R. de Wind, G. van den Eynden, S. Garaud, L. Buisseret, C. Naveaux, C. Sotiriou, D. Larsimont, M. Piccart, K. Willard-Gallo
Journal: Annals of Oncology (2016)
TMIC-15. MUTANT IDH1 SUPPRESSES THE PROCOAGULANT AND PROMALIGNANT EFFECTS OF TISSUE FACTOR IN GLIOMAS
Authors: Dusten Unruh, Snezana Mirkov, C. David James, Craig Horbinski
Journal: Neuro-Oncology (2016)

Gliomas are one of the cancers most at risk of causing life-threatening venous thromboemboli (VTE). Previously, we discovered that gliomas with mutations in isocitrate dehydrogenase (IDH1mut) are much less likely to contain intratumoral microthrombi, and are much less likely to cause peripheral VTE, compared to IDH1 wild-type (IDH1wt) gliomas. We also found that IDH1mut gliomas have methylation-associated suppression of Tissue Factor (TF), a key initiator of thrombosis. Furthermore, prior studies have shown that TF directly increases the malignancy of many cancers through multiple transmembrane signaling pathways. In the current study, we further explored the significance of TF in IDH1wt and IDH1mut gliomas. Three IDH1wt patient derived cell lines (GBM6, GBM12, GBM43) had high levels of TF protein and TF procoagulant activity in vitro, whereas 3 lines of patient-derived endogenous IDH1mut glioma cells (TB09, GBM164, BT142) had very low TF expression and activity. Exogenous treatment with the product of IDH1mut enzyme, D-2-hydroxyglutarate, suppressed the procoagulant activity of TF by up to 28% in IDH1wt cells. Likewise, induced expression of IDH1mut suppressed TF activity by 36% in IDH1wt cells. Thus far, in an ongoing prospective assessment of TF activity in the systemic circulation of glioma patients, 7/32 (22%) IDH1wt patients have had highly active circulating TF (defined as >2.0 pg/mL factor Xa generation), whereas 0/15 (0%) IDH1mut gliomas did—a pattern already trending toward significance (P=0.08). Among the 3 IDH1wt glioma cell lines, there was a direct correlation between TF expression and transwell migration, and TF knockdown with shRNA decreased migration by 93% (P=0.024). TF knockdown also reduced the average growth rate of orthotopic IDH1wt patient-derived glioma xenografts by 92%, as measured with bioluminescence imaging (P=0.03). These findings further indicate that suppression of TF expression and activity may be a critical component of the less thrombogenic, and less malignant, IDH1mut phenotype.
NIMG-62. GENERALIZED Q-SPACE MRI (GQI) REVEALED GLIOBLASTOMA ARCHITECTURE THAT REFLECT THE DEGREE OF TUMOR NECROSIS: A POTENTIAL PROGNOSTIC IMAGING BIOMARKER
Authors: Clark Chen, Erik Taylor, Yao Ding, Shan Zhu, Phillip Alexander, Leon Lin, George Aninwene, Matthew Hoffman, Anita Mahajan, Abdallah Mohamed, Nathan McDannold, Clifton Fuller, Richard Gilbert
Journal: Neuro-Oncology (2016)

Glioblastoma is characterized by significant histologic heterogeneity, with varying degrees of tumor necrosis. We utilized the generalized Q-space Imaging (GQI) algorithm to analyze MRI derived from rodent glioblastoma models and clinical images derived from glioblastoma patients. Correlative analysis was performed between GQI findings, the degree of tumor necrosis, and overall survival. In rodent glioblastoma models, GQI showed that glioblastomas possess a central region (termed “core”) characterized by disorganized diffusion and a highly coherent periphery (termed “shell”) characterized by highly organized diffusion tracts. Histologic analysis revealed that the core region was associated with a high degree of necrosis while the shell regions harbored anaplastic cells and elevated mitotic index. When GQI was applied to MRIs available through The Cancer Imaging Atlas (TCGA), we found that the core/shell (c/s ratio) varied significantly between patients. Moreover, the c/s ratio of glioblastomas linearly correlated with the degrees of necrosis observed on histologic sections (p<0.01). The degree of necrosis, in turn, inversely associated with patient survival. These findings were validated in an independent cohort of glioblastoma patients (n=24). GQI demonstrates regional differences in diffusion properties in glioblastomas. These differences reflect the extent of tumor necrosis and were prognostic of overall survival. These results suggest that GQI represent a non-invasive tool for assessing the anatomical organization glioblastoma and may offer prognostic value in the clinical setting.
Endoscopic treatment of an esophageal duplication cyst
Authors: Jun Nishikawa, Misato Nagao, Ryo Ogawa, Sho Sasaki, Atsushi Goto, Takeshi Okamoto, Isao Sakaida
Journal: Endoscopy (2017)

A 34-year-old woman was referred to our hospital because of the development of dysphagia and weight loss. Esophagogastroduodenoscopy (EGD) showed a submucosal tumor in the middle of the esophagus ([Fig. 1 a]) and endoscopic ultrasonography (EUS) revealed a bilobed cystic lesion within the submucosal layer. Computed tomography (CT) of the chest showed a well-defined, bilobed, cystic mass in the mediastinum.
Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone
Authors: Y. Yan, C. Robert, J. Larkin, P.A. Ascierto, B. Dreno, M. Maio, C. Garbe, P.B. Chapman, J.A. Sosman, M.J. Wongchenko, J.J. Hsu, I. Chang, I. Caro, I. Rooney, G. McArthur, A. Ribas
Journal: Annals of Oncology (2016)